Organogenesis (ORGO) Fundamental Analysis: Revenue, Earnings & Valuation

6.32 / 10

Outperform

Fundamentally, ORGO receives an Outperform rating with a 6.32/10 score. Cash‑MV and strong YoY revenue growth drive the upside, while PB‑ROE and a modest gross profit margin raise concerns. Overall, the financial health is solid but not without weaknesses.

Analysis Checks(8/10)

Revenue-MV

Value0.81

Score3/3

Weight43.94%

1M Return9.01%

Total operating revenue (YoY growth rate %)

Value17.04

Score2/3

Weight-3.36%

1M Return-1.06%

Inventory turnover ratio

Value4.92

Score2/3

Weight-3.92%

1M Return-1.21%

Gross profit margin (%)

Value75.62

Score0/3

Weight-20.37%

1M Return-7.24%

PB-ROE

Value0.03

Score0/3

Weight14.01%

1M Return3.23%

Income tax / Total profit (%)

Value21.16

Score3/3

Weight6.34%

1M Return1.47%

Fixed assets turnover ratio

Value3.95

Score2/3

Weight-1.85%

1M Return-0.51%

Cost of sales ratio (%)

Value24.38

Score2/3

Weight-13.38%

1M Return-4.42%

Asset-MV

Value-0.55

Score2/3

Weight53.85%

1M Return12.22%

Cash-MV

Value0.52

Score2/3

Weight24.74%

1M Return5.94%

Is ORGO undervalued or overvalued?

ORGO scores 6.32/10 on fundamentals and holds a Discounted valuation at present. Backed by its 4.89% ROE, 6.56% net margin, 14.71 P/E ratio, 0.68 P/B ratio, and 1700.00% earnings growth, these metrics solidify its Outperform investment rating.